Exponent Inc filings document operating results, Regulation FD disclosures, capital-return actions, and governance matters for a science and engineering consulting company. Recent Form 8-K reports record quarterly financial results, dividend declarations, and share repurchase authorizations tied to the company’s common stock.
Proxy materials cover shareholder voting matters, director elections, executive compensation, pay-versus-performance tables, and board governance. The filing record also includes material-event disclosures related to leadership and corporate governance, along with capital-structure disclosures relevant to Exponent’s public-company reporting.
Form 144 filed for EXPO reports a proposed sale tied to an option exercise and recent 10b5-1 plan sales. The filer exercised 4,905 common shares on 09/15/2025, paid in cash, with an aggregate market value reported as $343,595.25. The issuer's shares outstanding are listed as 50,501,135, and the proposed sale is to occur on 09/15/2025 through Morgan Stanley Smith Barney LLC on NASDAQ. The filing also discloses two 10b5-1 sales by Catherine Ford Corrigan on 08/14/2025 totaling 4,896 shares with combined gross proceeds of $348,042.61. The notice includes the standard attestation regarding material nonpublic information.
Catherine Corrigan, President & CEO and Director of Exponent Inc (EXPO), reported option exercises and related stock sales on 08/14/2025. She exercised two non-qualified stock option tranches: 3,226 options at a $25.405 exercise price and 2,380 options at $29.05. Concurrent with exercise, shares were sold: 3,226 shares at $70.9347 and 1,670 shares at $71.3816; the filing states the sale was to cover the option exercise price and taxes. After these transactions her beneficial ownership of common stock was reported as 82,052 shares.
Notice of proposed sale under Rule 144 for Exponent Inc (EXPO). The filer proposes to sell 4,896 shares of common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of $355,694.40. The securities are listed on NASDAQ and approximately dated for sale on 08/14/2025. The shares were acquired on 08/14/2025 by exercise of stock options from the issuer and payment was made in cash on the same date. The form states there were no securities sold in the past three months by the reporting person and includes the standard representation that the signer does not possess undisclosed material adverse information.
Joseph Sala, Group Vice President at Exponent Inc (EXPO), reported the sale of 1,595 shares of common stock on 08/12/2025 at a price of $70.6406 per share. The Form 4 discloses this Section 16 transaction and shows reported beneficial ownership of 0 shares following the sale. No derivative securities or additional transactions are listed on the form, and no explanatory detail is provided within the filing.
This Form 144 filed for Exponent Inc (EXPO) notifies of a proposed sale under Rule 144 of 1,595 common shares with an aggregate market value of $112,671.76, to be executed through Morgan Stanley Smith Barney LLC with an approximate sale date of 08/12/2025. The filing identifies the securities as restricted stock acquired in two tranches: 833 shares on 03/12/2021 and 762 shares on 03/12/2025.
The notice reports 50,501,135 shares outstanding, making the proposed sale represent a vanishingly small portion of the company (roughly 0.003% of outstanding shares). No securities were reported sold by the filer in the past three months. The document is a routine insider sale notice and provides transparent transactional detail but no new operational or financial information about the company.
Exponent reported modest top-line growth with mixed profitability. Second-quarter revenues were $141,962,000, up 1% year-over-year, driven by higher billing rates in engineering services. Net income fell 9% to $26,553,000 and diluted EPS declined to $0.52 from $0.57, reflecting higher compensation-related costs and lower utilization.
The firm generated $43,496,000 of operating cash flow in the first six months and held $231,801,000 in cash and cash equivalents at period end. Billable hours declined 6% and utilization fell to 72%, while a large change in the fair value of deferred compensation plan assets increased other income but also raised corporate compensation expense, materially reducing operating income for the quarter. The company continued shareholder returns via $0.30 per-share quarterly dividend and increased share repurchases ($32.68M year-to-date).